The biological basis of high-grade DLBCL with MYC, BCL2, and/or BCL6 rearrangements (HGBL-DH/TH-BCL2) was explored by Ennishi et al. They analyzed whole-exome sequencing, RNA-seq, and targeted resequencing and other data from patients with GCB-DLBCL (n = 157), including cases of HGBL-DH/TH-BCL2 (n = 25). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.